Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Financiere de TubizeCHIX:TUBB 43 Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus rates CHIX:TUBB with a GF Score™ of 43/100. The stock has 1 warning sign investors should review. Among 298 Biotechnology companies, Financiere de Tubize ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Financiere de Tubize's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Financiere de Tubize was 1.30. The lowest was 0.00. And the median was 0.50.
CHIX:TUBb's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.23 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Financiere de Tubize Debt-to-EBITDA Related Terms
Financiere de Tubize Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Financiere de Tubize's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:TUBB vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Financiere de Tubize's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Financiere de Tubize Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Financiere de Tubize's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Financiere de Tubize (CHIX:TUBB) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Financiere de Tubize. According to the industry distribution chart, Financiere de Tubize ranks #999999 out of 298 companies in the Biotechnology industry.
Is Financiere de Tubize's Debt-to-EBITDA too high?
Financiere de Tubize's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Financiere de Tubize ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Financiere de Tubize has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Financiere de Tubize's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Financiere de Tubize ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Financiere de Tubize in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Financiere de Tubize. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Financiere de Tubize's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Financiere de Tubize stock overvalued right now?
Financiere de Tubize (CHIX:TUBB) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Financiere de Tubize's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Financiere de Tubize (CHIX:TUBB), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
43GF Score
Get the complete analysis for CHIX:TUBB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:TUBB has been successfully added to your 
